|
Hyperglycemia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, our findings suggest that the common Glu23Lys polymorphism in KIR6.2 is not necessarily associated with beta-cell dysfunction or insulin resistance but with diminished suppression of glucagon secretion in response to hyperglycemia.
|
12196481 |
2002 |
|
Hyperglycemia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The decrease in glucagon AUC and decreased suppression of glucagon AUC with hyperglycemia suggest that mutations in HNF-4alpha may lead to alpha-cell as well as beta-cell secretory defects or a reduction in pancreatic islet mass.
|
9356021 |
1997 |
|
Hyperglycemia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
There is ample evidence that in type 2 diabetes mellitus (T2DM), in addition to a progressive decline in β-cell function and associated insulin resistance in a number of insulin-sensitive tissues, alterations in glucagon secretion are also present and may play an important role in the pathogenesis of hyperglycemia both in the fasting and in the postprandial state.
|
30230173 |
2018 |
|
Hyperglycemia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Diabetes-associated variation (T allele at rs7903146) in TCF7L2 may impair the ability of hyperglycemia to suppress glucagon (45 ± 2 vs. 47 ± 2 vs. 60 ± 5 ng/L for CC, CT, and TT, respectively, P = 0.02).
|
22461567 |
2012 |
|
Hyperglycemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
The effect of GLP-1 to increase insulin concentrations relative to placebo levels tended to be lower during euglycaemia in ESRD and was significantly reduced during hyperglycaemia (50 [8-72]%, P=0.03).
|
31608934 |
2020 |
|
Hyperglycemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
GLP-1 can correct hyperglycemia in diabetic patients, even in those no longer responding to hypoglycemic agents.
|
10415574 |
1999 |
|
Hyperglycemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Diabetes is characterized by hyperglycemia due to impaired insulin secretion and aberrant glucagon secretion resulting from changes in pancreatic islet cell function and/or mass.
|
30805033 |
2019 |
|
Hyperglycemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Although glucagon-like peptide 1- (GLP-1-) based therapy of hyperglycemia in burn injury has shown great potential in clinical trials, its safety is seldom evaluated.
|
30800001 |
2019 |
|
Hyperglycemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Activation of intestinal olfactory receptor stimulates glucagon-like peptide-1 secretion in enteroendocrine cells and attenuates hyperglycemia in type 2 diabetic mice.
|
29070885 |
2017 |
|
Hyperglycemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
The secretion of glucagon is controlled by blood glucose and inappropriate secretion of glucagon contributes to hyperglycaemia in diabetes.
|
29305624 |
2018 |
|
Hyperglycemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
The increased blood glucagon might contribute to the hyperglycemia observed in the PFOA-treated group compared with the control group.
|
28947262 |
2017 |
|
Hyperglycemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Pasireotide-induced hyperglycemia occurs early, within the first 3 months of treatment, due to a decrease in insulin secretion secondary to a fall in secretion of GLP-1 and GIP, and potentially also due to a direct inhibitory effect of pasireotide on beta cells.
|
28579289 |
2017 |
|
Hyperglycemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Knockdown of p52 lowers glucagon-stimulated hyperglycemia, while p52 overexpression augments glucagon response.
|
31541100 |
2019 |
|
Hyperglycemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Unimolecular dual incretins derived from hybridized glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) sequences have demonstrated synergistic reduction of adiposity in animal models and reductions of hyperglycemia in short-duration human trials.
|
28768173 |
2017 |
|
Hyperglycemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Glucagon-like peptide-1 stimulates insulin secretion during hyperglycaemia, suppresses glucagon secretion, stimulates (pro)insulin biosynthesis and decelerates gastric emptying and acid secretion.
|
10096792 |
1999 |
|
Hyperglycemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
In conclusion, a single administration of clozapine increased the serum concentration of glucose in rats, and adrenaline and/or glucagon would be associated with clozapine-induced acute hyperglycemia.
|
30068879 |
2018 |
|
Hyperglycemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Dupre demonstrated that secretin given intravenously with glucose increased its rate of disappearance from the blood, McIntyre and co-workers established that hyperglycaemia evoked by oral glucose stimulated more insulin secretion than comparable hyperglycaemia produced by intravenous glucose and Marks and Samols established the insulinotropic properties of glucagon.
|
28838782 |
2018 |
|
Hyperglycemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
In addition, glucagon responses are inappropriately increased and importantly contribute to both fasting and postprandial hyperglycemia.
|
28605280 |
2017 |
|
Hyperglycemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Inoculation of streptozotocin (STZ)-treated mice with vCVB(dm)GLP-1 was found to suppress development of hyperglycemia and increase insulin production relative to mice treated with STZ alone or with empty vector.
|
21937637 |
2011 |
|
Hyperglycemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Plasma glucagon rose after glucagon delivery (1231±187 vs. 16±1 pg/mL at 30 minutes, p=0.001).No rebound hyperglycemia occurred.
|
31714583 |
2020 |
|
Hyperglycemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Exposure to glucagon-like peptide 1 (GLP1) can ameliorate hyperglycemia in diabetic mice and restore the beta cell mass.
|
31001561 |
2019 |
|
Hyperglycemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Incretin hormones (glucagon-like peptide-1 [GLP-1] and gastric inhibitory polypeptide [GIP]) may play a role in the development of glucose intolerance and hyperglycemia in patients with hyperthyroidism.
|
28452237 |
2017 |
|
Hyperglycemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
With the aim of investigating glucose-mediated glucose disposal (glucose effectiveness [GE]) in 15 (3 female and 12 male subjects) insulin-resistant normoglycemic relatives of patients with type 2 diabetes (DM2), and 15 age-, sex-, and BMI-matched control subjects without a family history of DM2, we performed 2 studies: 1) a 5-h euglycemic near-normoinsulinemic pancreatic clamp with somatostatin (360 microg/h), insulin (0.25 mU x kg(-1) x min(-1)), glucagon (0.5 ng x kg(-1) x min(-1)), growth hormone (6 ng x kg(-1) x min(-1)), and tritiated glucose infusion and indirect calorimetry; and 2) on a separate day, an identical 5-h clamp but at hyperglycemia (approximately 12 mmol/l) over the last 2 h. Fasting plasma insulin (PI) concentrations were elevated in the relatives compared with control subjects (49 +/- 6 vs. 32 +/- 5 pmol/l, P < 0.04), whereas plasma glucose (PG) was not (5.6 +/- 0.1 vs. 5.5 +/-0.1 mmol/l).
|
10909980 |
2000 |
|
Hyperglycemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
However, GIP stimulates glucagon secretion even at hyperglycemia in people with T2D, suggesting that inappropriate GIPR activity in α-cells contributes to the pathogenesis of T2D.
|
31785304 |
2020 |
|
Hyperglycemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Glucagon signaling increases hepatic glucose output, and hyperglucagonemia is partly responsible for the hyperglycemia in diabetes making glucagon an attractive target for therapeutic intervention.
|
31653720 |
2020 |